XML 45 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summarized Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
The following financial information reflects all adjustments, which includes all normal recurring adjustments and the items described in (1) to (2) below, which are, in the opinion of management, necessary for a fair statement of the consolidated financial results of the interim periods. Summarized quarterly data for 2017 and 2016 is as follows:

 
 
 
 
 
 
 
 
 
2017 Quarter Ended
 
March 31
 
June 30 (1)
 
September 30 (1)
 
December 31 (1)
 
(in thousands, except per share amounts)
Revenue
$
2,696

 
$
7,125

 
$
—

 
$
—

Loss from continuing operations
$
(21,126
)
 
$
(22,453
)
 
$
(42,660
)
 
$
(39,783
)
(Loss) income from discontinued operations
$
(181
)
 
$
(555
)
 
$
(134
)
 
$
75

Net loss
$
(21,307
)
 
$
(23,008
)
 
$
(42,794
)
 
$
(39,708
)
Net loss per share, basic and diluted
$
(0.86
)
 
$
(0.93
)
 
$
(1.68
)
 
$
(1.17
)

 
2016 Quarter Ended
 
March 31
 
June 30
 
September 30 
 
December 31(2)
 
(in thousands, except per share amounts)
Revenue
$
9,206

 
$
2,088

 
$
6,570

 
$
10,986

Loss from continuing operations
$
(10,220
)
 
$
(18,246
)
 
$
(16,618
)
 
$
(23,602
)
(Loss) income from discontinued operations
$
(169
)
 
$
(582
)
 
$
(379
)
 
$
109

Net loss
$
(10,389
)
 
$
(18,828
)
 
$
(16,997
)
 
$
(23,493
)
Net loss per share, basic and diluted
$
(0.42
)
 
$
(0.76
)
 
$
(0.69
)
 
$
(0.95
)

(1)
In April 2017, the Company completed fulfillment of the remaining open orders under its manufacturing and supply agreement with Endo and the Company no longer has a source of recurring revenue.
(2)
Net loss from continuing operations included asset impairment charges of $8.4 million for long-lived assets and prepaid royalties associated with the production of Sumavel DosePro (See Note 6).